These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

564 related items for PubMed ID: 28445498

  • 1. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).
    Schneider R, Bellenberg B, Hoepner R, Kolb EM, Ellrichmann G, Haghikia A, Gold R, Lukas C.
    PLoS One; 2017; 12(4):e0176415. PubMed ID: 28445498
    [Abstract] [Full Text] [Related]

  • 2. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.
    JAMA Neurol; 2018 Jul 01; 75(7):827-833. PubMed ID: 29532061
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. JCV detection in multiple sclerosis patients treated with natalizumab.
    Sadiq SA, Puccio LM, Brydon EW.
    J Neurol; 2010 Jun 01; 257(6):954-8. PubMed ID: 20052484
    [Abstract] [Full Text] [Related]

  • 5. Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions.
    Schneider R, Bellenberg B, Hoepner R, Ellrichmann G, Gold R, Lukas C.
    Front Neurol; 2017 Jun 01; 8():454. PubMed ID: 28928709
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
    Werner MH, Huang D.
    J Neurovirol; 2016 Dec 01; 22(6):871-875. PubMed ID: 27198748
    [Abstract] [Full Text] [Related]

  • 7. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
    Domínguez-Mozo MI, García-Montojo M, Arias-Leal A, García-Martínez Á, Santiago JL, Casanova I, Galán V, Arroyo R, Fernández-Arquero M, Alvarez-Lafuente R.
    Eur J Neurol; 2016 Jan 01; 23(1):182-9. PubMed ID: 26498276
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy.
    Chang L, Ernst T, Tornatore C, Aronow H, Melchor R, Walot I, Singer E, Cornford M.
    Neurology; 1997 Apr 01; 48(4):836-45. PubMed ID: 9109865
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV.
    Simone IL, Federico F, Tortorella C, Andreula CF, Zimatore GB, Giannini P, Angarano G, Lucivero V, Picciola P, Carrara D, Bellacosa A, Livrea P.
    J Neurol Neurosurg Psychiatry; 1998 Apr 01; 64(4):516-23. PubMed ID: 9576546
    [Abstract] [Full Text] [Related]

  • 15. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
    Schweitzer F, Ladwig A, Opala S, Laurent S, Schroeter M, Goelz S, Fink GR, Wieland U, Silling S, Warnke C.
    Mult Scler Relat Disord; 2024 Jul 01; 87():105664. PubMed ID: 38735204
    [Abstract] [Full Text] [Related]

  • 16. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    Skarlis C, Papadopoulos V, Raftopoulou S, Mavragani CP, Evangelopoulos ME.
    J Neurol Sci; 2024 Jun 15; 461():123046. PubMed ID: 38761670
    [Abstract] [Full Text] [Related]

  • 17. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V, Bramanti P, Mazzon E.
    Mult Scler Relat Disord; 2018 Feb 15; 20():93-99. PubMed ID: 29353737
    [Abstract] [Full Text] [Related]

  • 18. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
    Piu C, Ibba G, Bertoli D, Capra R, Uleri E, Serra C, Imberti L, Dolei A.
    J Neurovirol; 2020 Feb 15; 26(1):133-137. PubMed ID: 31468472
    [Abstract] [Full Text] [Related]

  • 19. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Hodel J, Darchis C, Outteryck O, Verclytte S, Deramecourt V, Lacour A, Zins M, Pruvo JP, Vermersch P, Leclerc X.
    Neurology; 2016 Apr 19; 86(16):1516-23. PubMed ID: 27009257
    [Abstract] [Full Text] [Related]

  • 20. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ.
    Neurologist; 2006 Nov 19; 12(6):293-8. PubMed ID: 17122725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.